Study on the Composite Endpoint Event of PCSK9 Inhibitor in Patients With Very High Risk of ASCVD and Cancer

Conditions:   ASCVD;   Atherosclerotic Cardiovascular Disease;   Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor;   Cancer Interventions:   Drug: Evolocumab;   Drug: Statin Sponsors:   Xiang Xie;   Xinjiang Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials